Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|September 11, 2020
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancerH Adderley, F H Blackhall, C R Lindsay
Cancer Treatment Reviews|April 9, 2016
Thymic malignancies: Moving forward with new systemic treatmentsJ Remon, C R Lindsay, M V Bluthgen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2018
KRAS: Reasons for optimism in lung cancerC R Lindsay, M Jamal-Hanjani, M Forster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Germline and sporadic cancers driven by the RAS pathway: parallels and contrastsV Dunnett-Kane, E Burkitt-Wright, F H Blackhall, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignanciesJ Remon, N Abedallaa, E Taranchon-Clermont, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Oncogene|June 7, 2011
Regulation of mitosis and taxane response by Daxx and Rassf1S Giovinazzi, C R Lindsay, V M Morozov, et al.
Cell Death & Disease|April 6, 2026
The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancerJ Searle, M Menotti, W J McDaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerE Pailler, N Auger, C R Lindsay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trialR Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Pageof 2